Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
NeoVax · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| Neovax in Combination with Ipilimumab | EXPERIMENTAL | Patients will undergo surgery with the intent to resect the primary kidney tumor Neovax is a combination of Poly-ICLC and Neoantigen Peptides Priming doses of NeoVax will be administered on days 1, 4, 8, 15, and 22 * In the boost phase, vaccine will be administered on days 78 (week 12) and 134 (week 20 Ipilimumab will be injected within 1 cm of each NeoVax administration |
| NeoVax alone | EXPERIMENTAL | Patients will undergo surgery with the intent to resect the primary kidney tumor Neovax is a combination of Poly-ICLC and Neoantigen Peptides Priming doses of NeoVax will be administered on days 1, 4, 8, 15, and 22 * In the boost phase, vaccine will be administered on days 78 (week 12) and 134 (week 20) |
| Name | Type | Description |
|---|---|---|
| NeoVax | DRUG | combination of Neoantigen peptides and poly-ICLC |
| Ipilimumab | DRUG | local administration of ipilimumab |
Inclusion Criteria for Initial Registration: * Ability to understand and the willingness to sign a written informed consent document. * Patients should have suspected stage III or stage IV clear cell renal cell carcinoma (ccRCC), with anticipation that all disease can be surgically resected. Confir...
Top 20 of 36 competitors
NeoVax is an investigational small molecule being studied for the treatment of kidney cancer. It is currently in Phase 1 clinical development. The drug is being evaluated in a clinical trial that combines NeoVax with ipilimumab in patients with renal cell carcinoma.
NeoVax is a small molecule therapeutic being developed for kidney cancer. The specific molecular target of NeoVax has not been disclosed in the available information. The drug is currently being studied in a Phase 1 clinical trial in combination with ipilimumab for the treatment of renal cell carcinoma.
NeoVax is being developed by Bristol-Myers Squibb Company, which trades on the New York Stock Exchange under the ticker symbol BMY. The company is currently conducting a Phase 1 clinical trial of NeoVax in patients with kidney cancer.
NeoVax is in Phase 1 clinical development. It is an investigational drug and has not been approved by the FDA. The ongoing Phase 1 trial is studying NeoVax in combination with ipilimumab for the treatment of kidney cancer.
NeoVax is being studied in one active clinical trial with the identifier NCT02950766. This Phase 1 trial, titled 'NeoVax Plus Ipilimumab in Renal Cell Carcinoma,' is enrolling patients with kidney cancer in the United States. The trial is not recruiting new participants and has a target enrollment of 19 patients.
No, NeoVax is not the same as ipilimumab. NeoVax is an investigational small molecule being developed by Bristol-Myers Squibb for kidney cancer. Ipilimumab is a separate drug that is being studied in combination with NeoVax in a Phase 1 clinical trial for the treatment of renal cell carcinoma.